Compare FNWB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | IMUX |
|---|---|---|
| Founded | 1923 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 75.2M |
| IPO Year | 2012 | 2013 |
| Metric | FNWB | IMUX |
|---|---|---|
| Price | $8.64 | $1.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $13.50 | $4.25 |
| AVG Volume (30 Days) | 28.0K | ★ 3.0M |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | 36.00 | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,000.00 | N/A |
| Revenue This Year | $19.24 | N/A |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.05 | $0.51 |
| 52 Week High | $10.98 | $1.51 |
| Indicator | FNWB | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 21.39 | 55.82 |
| Support Level | $8.16 | $0.64 |
| Resistance Level | $9.00 | $1.17 |
| Average True Range (ATR) | 0.29 | 0.13 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 2.88 | 33.55 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.